Provided by Tiger Trade Technology Pte. Ltd.

HENLIUS

71.700
+5.7008.64%
Volume:1.75M
Turnover:123.26M
Market Cap:38.93B
PE:41.97
High:72.450
Open:66.600
Low:66.100
Close:66.000
52wk High:92.000
52wk Low:23.000
Shares:543.00M
HK Float Shares:346.07M
Volume Ratio:2.41
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.708
ROE:23.72%
ROA:4.45%
PB:8.69
PE(LYR):41.97
PS:5.16

Loading ...

Shanghai Henlius Biotech Receives CSRC Approval for H Share Full Circulation

Reuters
·
Jan 16

Henlius (02696): Biologics License Application for Hanbeitai® (Bevacizumab Injection) Accepted by U.S. FDA

Stock News
·
Jan 13

FDA Accepts Biologics License Application for Henlius Hanbeitai Bevacizumab Injection

Reuters
·
Jan 13

Shanghai Henlius Biotech Inc - Biologics License Application for Hanbeitai (Bevacizumab Injection) Accepted by FDA

THOMSON REUTERS
·
Jan 13

Hong Kong Stock Movement | HENLIUS (02696) Surges Over 8% Again, Broad-Spectrum Anti-Tumor PD-L1 ADC HLX43 Phase II Data for End-Line Esophageal Squamous Cell Carcinoma First Released

Stock News
·
Jan 13

HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma

Stock News
·
Jan 08

Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After HLX37 Enters Phase 1 Clinical Study

Simply Wall St.
·
Jan 08

HENLIUS (02696.HK) Surges Nearly 9%

Deep News
·
Jan 05

Hong Kong Stock Movement | HENLIUS (02696) Surges Nearly 9% as IND Applications for Three Innovative Solid Tumor Drugs Are Accepted Concurrently

Stock News
·
Jan 05

Singapore's GIC Boosts Stake in Henlius with 177,000 Shares at HK$56.76 Each

Deep News
·
Jan 04

Singapore's GIC Increases Stake in HENLIUS (02696) by 177,000 Shares at HK$56.76 Per Share

Stock News
·
Jan 02

Shanghai Henlius Biotech Inc. Held Extraordinary General Meeting

Reuters
·
Dec 31, 2025

Henlius Biotech Doses First Patient in Phase 1 Trial of Tumor Drug

MT Newswires Live
·
Dec 29, 2025

Henlius CEO to Deliver Keynote at J.P. Morgan Healthcare Conference

Reuters
·
Dec 23, 2025

Shanghai Henlius Biotech (SEHK:2696) Valuation Check After US FDA IND Approval for HLX18 Biosimilar Trial

Simply Wall St.
·
Dec 21, 2025

Henlius Biotech Gets US FDA Nod to Conduct Trial of Tumor Drug

MT Newswires Live
·
Dec 19, 2025

HENLIUS (02696): FDA Approves Phase 1 Clinical Trial Application for HLX18, a Nivolumab Biosimilar, for Treatment of Various Solid Tumors

Stock News
·
Dec 19, 2025

FDA Approves Shanghai Henlius Biotech's IND Application for Nivolumab Biosimilar HLX18 Phase 1 Trial

Reuters
·
Dec 19, 2025

Shanghai Henlius Biotech Inc - Phase 1 Clinical Trial of Nivolumab Biosimilar Hlx18 Approved by United States FDA

THOMSON REUTERS
·
Dec 19, 2025

BRIEF-Shanghai Henlius Biotech Says NDA For Hansizhuang Granted Priority Review By NMPA

Reuters
·
Dec 12, 2025